Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database

BACKGROUND: Elevated inflammatory cytokines in Coronavirus disease 2019 (COVID‐19) affect the lungs leading to pneumonitis with a poor prognosis. Tocilizumab, a type of humanized monoclonal antibody antagonizing interleukin-6 receptors, is currently utilized to treat COVID-19. The present study revi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Expert Opin Drug Saf
Main Authors: Charan, Jaykaran, Dutta, Siddhartha, Kaur, Rimplejeet, Bhardwaj, Pankaj, Sharma, Praveen, Ambwani, Sneha, Jahan, Iffat, Abubakar, Abdullahi Rabiu, Islam, Salequl, Hardcastle, Timothy Craig, Rahman, Nor Azlina A, Lugova, Halyna, Haque, Mainul
Formato: Artigo
Idioma:Inglês
Publicado: Taylor & Francis 2021
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8290369/
https://ncbi.nlm.nih.gov/pubmed/34162299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14740338.2021.1946513
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares